INmune Bio partners with Quantum Computing Inc. on Alzheimer’s drug research
QUBT•INmune Bio and Quantum Computing Inc. will use quantum optimization, AI and analytics to expand research on XPro1595. The work will use clinical and public datasets to identify potential indications and biomarkers.
1. Research collaboration
The companies will use QCi’s Dirac-3S quantum optimization machine with clinical and public datasets to explore new indications and biomarkers for XPro1595, which selectively inhibits soluble TNF. They will compare the results with conventional statistical and machine-learning methods. The first stage is QCi’s first commercial pharma and biotech customer engagement, with options for additional work as programs advance.
